{"id":"alglucerase","rwe":[],"tags":[{"label":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A16AB01","category":"atc"},{"label":"Active","category":"status"},{"label":"Chronic non-neuropathic Gaucher's disease","category":"indication"},{"label":"Genzyme","category":"company"},{"label":"Approved 1990s","category":"decade"}],"phase":"marketed","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Sanofi","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALGLUCERASE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:40:58.693541+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Alglucerase","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:41:08.270585+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:41:07.021872+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALGLUCERASE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:41:07.197545+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucocerebroside hydrolytic enzyme","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:41:08.270555+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201633/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:41:07.898177+00:00"}},"allNames":"ceredase","offLabel":[],"synonyms":["alglucerase","ceredase"],"timeline":[{"date":"1991-04-05","type":"positive","source":"DrugCentral","milestone":"FDA approval (Genzyme)"}],"aiSummary":"Ceredase (ALGLUCERASE) is a hydrolytic lysosomal glucocerebroside-specific enzyme used to treat chronic non-neuropathic Gaucher's disease. It was originally developed and is currently owned by Genzyme. This small molecule modality was FDA-approved in 1991 for its approved indications. The commercial status of Ceredase is not explicitly stated, but it is likely patented. Key safety considerations include the potential for hypersensitivity reactions and the need for careful monitoring of patients.","brandName":"Ceredase","ecosystem":[{"indication":"Chronic non-neuropathic Gaucher's disease","otherDrugs":[{"name":"taliglucerase alfa","slug":"taliglucerase-alfa","company":"Pfizer"},{"name":"velaglucerase alfa","slug":"velaglucerase-alfa","company":"Shire Human Genetic"}],"globalPrevalence":null}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme","explanation":"","oneSentence":"","technicalDetail":"Ceredase is a recombinant form of the enzyme glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, thereby reducing the accumulation of glucocerebroside in the lysosomes of Gaucher cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Alglucerase","title":"Alglucerase","extract":"Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues."},"commercial":{"launchDate":"1991","_launchSource":"DrugCentral (FDA 1991-04-05, GENZYME)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5129","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALGLUCERASE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALGLUCERASE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Alglucerase","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:36:58.654656","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:41:09.563608+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"imiglucerase","drugSlug":"imiglucerase","fdaApproval":"1994-05-23","relationship":"same-class"},{"drugName":"agalsidase beta","drugSlug":"agalsidase-beta","fdaApproval":"2003-04-24","relationship":"same-class"},{"drugName":"laronidase","drugSlug":"laronidase","fdaApproval":"2003-04-30","relationship":"same-class"},{"drugName":"sacrosidase","drugSlug":"sacrosidase","fdaApproval":"1998-04-09","relationship":"same-class"},{"drugName":"alglucosidase alfa","drugSlug":"alglucosidase-alfa","fdaApproval":"2006-04-28","relationship":"same-class"},{"drugName":"galsulfase","drugSlug":"galsulfase","fdaApproval":"2005-05-31","relationship":"same-class"},{"drugName":"idursulfase","drugSlug":"idursulfase","fdaApproval":"2006-07-24","relationship":"same-class"},{"drugName":"velaglucerase alfa","drugSlug":"velaglucerase-alfa","fdaApproval":"2010-02-26","relationship":"same-class"},{"drugName":"taliglucerase alfa","drugSlug":"taliglucerase-alfa","fdaApproval":"2012-05-01","relationship":"same-class"},{"drugName":"elosulfase alfa","drugSlug":"elosulfase-alfa","fdaApproval":"2014-02-14","relationship":"same-class"},{"drugName":"asfotase alfa","drugSlug":"asfotase-alfa","fdaApproval":"2015-10-23","relationship":"same-class"},{"drugName":"sebelipase alfa","drugSlug":"sebelipase-alfa","fdaApproval":"2015-12-08","relationship":"same-class"},{"drugName":"velmanase","drugSlug":"velmanase","fdaApproval":"2023-02-16","relationship":"same-class"},{"drugName":"cerliponase alfa","drugSlug":"cerliponase-alfa","fdaApproval":"2017-04-27","relationship":"same-class"},{"drugName":"vestronidase alfa","drugSlug":"vestronidase-alfa","fdaApproval":"2017-11-15","relationship":"same-class"},{"drugName":"pegvaliase","drugSlug":"pegvaliase","fdaApproval":"2018-05-24","relationship":"same-class"},{"drugName":"pegunigalsidase alfa","drugSlug":"pegunigalsidase-alfa","fdaApproval":"2023-05-09","relationship":"same-class"},{"drugName":"avalglucosidase alfa","drugSlug":"avalglucosidase-alfa","fdaApproval":"2021-08-06","relationship":"same-class"},{"drugName":"olipudase alfa","drugSlug":"olipudase-alfa","fdaApproval":"2022-08-31","relationship":"same-class"}],"genericName":"alglucerase","indications":{"approved":[{"name":"Chronic non-neuropathic Gaucher's disease","source":"DrugCentral","snomedId":62201009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"imiglucerase","brandName":"imiglucerase","genericName":"imiglucerase","approvalYear":"1994","relationship":"same-class"},{"drugId":"agalsidase-beta","brandName":"agalsidase beta","genericName":"agalsidase beta","approvalYear":"2003","relationship":"same-class"},{"drugId":"laronidase","brandName":"laronidase","genericName":"laronidase","approvalYear":"2003","relationship":"same-class"},{"drugId":"sacrosidase","brandName":"sacrosidase","genericName":"sacrosidase","approvalYear":"1998","relationship":"same-class"},{"drugId":"alglucosidase-alfa","brandName":"alglucosidase alfa","genericName":"alglucosidase alfa","approvalYear":"2006","relationship":"same-class"},{"drugId":"galsulfase","brandName":"galsulfase","genericName":"galsulfase","approvalYear":"2005","relationship":"same-class"},{"drugId":"idursulfase","brandName":"idursulfase","genericName":"idursulfase","approvalYear":"2006","relationship":"same-class"},{"drugId":"velaglucerase-alfa","brandName":"velaglucerase alfa","genericName":"velaglucerase alfa","approvalYear":"2010","relationship":"same-class"},{"drugId":"taliglucerase-alfa","brandName":"taliglucerase alfa","genericName":"taliglucerase alfa","approvalYear":"2012","relationship":"same-class"},{"drugId":"elosulfase-alfa","brandName":"elosulfase alfa","genericName":"elosulfase alfa","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00001215","phase":"","title":"Genetic Studies of Lysosomal Storage Disorders","status":"ENROLLING_BY_INVITATION","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"1995-03-08","conditions":["Lysosomal Storage Disorders","Gaucher Disease","Parkinson Disease"],"enrollment":1000,"completionDate":""},{"nctId":"NCT04370665","phase":"NA","title":"Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease","status":"COMPLETED","sponsor":"InSightec","startDate":"2020-07-16","conditions":["Parkinson Disease"],"enrollment":4,"completionDate":"2022-02-25"},{"nctId":"NCT04127578","phase":"PHASE1,PHASE2","title":"Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2020-01-03","conditions":["Parkinson Disease"],"enrollment":32,"completionDate":"2030-12-31"},{"nctId":"NCT00302146","phase":"","title":"Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations","status":"COMPLETED","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2006-05-23","conditions":["Parkinson Disease","Gaucher Disease"],"enrollment":64,"completionDate":""},{"nctId":"NCT05565443","phase":"NA","title":"MR-guided Focused Ultrasound Plus GCase","status":"RECRUITING","sponsor":"InSightec","startDate":"2022-11-30","conditions":["Parkinsons Disease"],"enrollment":14,"completionDate":"2028-12-31"},{"nctId":"NCT03485677","phase":"PHASE3","title":"Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-04-11","conditions":["Gaucher's Disease Type I","Gaucher's Disease Type III"],"enrollment":57,"completionDate":"2025-12-12"},{"nctId":"NCT00358943","phase":"","title":"International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry","status":"RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"1991-04-01","conditions":["Gaucher Disease","Cerebroside Lipidosis Syndrome","Glucocerebrosidase Deficiency Disease","Glucosylceramide Beta-Glucosidase Deficiency Disease"],"enrollment":12000,"completionDate":"2034-01-31"},{"nctId":"NCT04228172","phase":"","title":"Genotypic Influences on Network Progression in Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwell Health","startDate":"2020-02-24","conditions":["Parkinson's Disease"],"enrollment":32,"completionDate":"2026-02-01"},{"nctId":"NCT04411654","phase":"PHASE1,PHASE2","title":"Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2021-06-29","conditions":["Gaucher Disease, Type 2"],"enrollment":7,"completionDate":"2028-05"},{"nctId":"NCT05819359","phase":"PHASE2","title":"Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bial R&D Investments, S.A.","startDate":"2023-03-31","conditions":["Parkinson's Disease"],"enrollment":237,"completionDate":"2026-07-31"},{"nctId":"NCT05304195","phase":"","title":"Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-17","conditions":["Dementia With Lewy Bodies"],"enrollment":236,"completionDate":"2026-06"},{"nctId":"NCT05222906","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-04-18","conditions":["Gaucher's Disease Type III"],"enrollment":43,"completionDate":"2026-10-30"},{"nctId":"NCT05518617","phase":"","title":"Molecular and Functional Imaging in Monogenic PD.","status":"RECRUITING","sponsor":"University of Exeter","startDate":"2022-07-01","conditions":["Parkinson Disease","Nervous System Disorder","Neurodegenerative Diseases","Neurodegenerative Disease, Hereditary","Parkinson's"],"enrollment":45,"completionDate":"2026-06-30"},{"nctId":"NCT04656600","phase":"PHASE4","title":"Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-03-02","conditions":["Gaucher's Disease"],"enrollment":12,"completionDate":"2023-10-12"},{"nctId":"NCT05287503","phase":"PHASE2","title":"Ambroxol as a Disease-modifying Treatment in GBA-PD","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2022-03-09","conditions":["Parkinson Disease","GBA Gene Mutation"],"enrollment":65,"completionDate":"2024-12-20"},{"nctId":"NCT05529992","phase":"PHASE3","title":"A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-01-03","conditions":["Gaucher Disease"],"enrollment":20,"completionDate":"2024-08-05"},{"nctId":"NCT06869499","phase":"NA","title":"Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Wladimir MAUHIN, Dr","startDate":"2025-05","conditions":["Splenomegaly","Splenectomy","Thrombopenia","Interstitial Lung Disease (ILD)","Hypocholesterolemia"],"enrollment":200,"completionDate":"2029-03-01"},{"nctId":"NCT02843035","phase":"PHASE2","title":"Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-01-04","conditions":["Gaucher Disease Type 1","Gaucher Disease Type 3"],"enrollment":12,"completionDate":"2026-10-30"},{"nctId":"NCT06451419","phase":"","title":"Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Juan Pablo Romero. MD, PhD","startDate":"2024-07-01","conditions":["Parkinson Disease"],"enrollment":40,"completionDate":"2026-08-31"},{"nctId":"NCT06193421","phase":"PHASE1,PHASE2","title":"High-Dose Ambroxol in GBA1-Related Parkinson","status":"UNKNOWN","sponsor":"Agyany Pharma LTD","startDate":"2023-10-24","conditions":["Parkinson Disease","GBA Gene Mutation"],"enrollment":40,"completionDate":"2025-04-30"},{"nctId":"NCT06167603","phase":"","title":"Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision Medicine Approach to Characterize Parkinson's Disease Clinical Trajectories","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2023-04-30","conditions":["Parkinson Disease"],"enrollment":140,"completionDate":"2026-04-01"},{"nctId":"NCT04145037","phase":"PHASE1,PHASE2","title":"Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease","status":"TERMINATED","sponsor":"AVROBIO","startDate":"2019-05-30","conditions":["Gaucher Disease"],"enrollment":8,"completionDate":"2023-08-21"},{"nctId":"NCT05815004","phase":"PHASE2,PHASE3","title":"An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3","status":"WITHDRAWN","sponsor":"AVROBIO","startDate":"2023-10","conditions":["Gaucher Disease, Type 3"],"enrollment":0,"completionDate":"2027-12"},{"nctId":"NCT04120506","phase":"PHASE4","title":"Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2016-01-10","conditions":["Gaucher Disease, Type 1"],"enrollment":15,"completionDate":"2022-01-01"},{"nctId":"NCT03519646","phase":"NA","title":"Eliglustat on Gaucher Disease Type IIIB","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-04-23","conditions":["Gaucher Disease, Type III"],"enrollment":4,"completionDate":"2020-09-11"},{"nctId":"NCT02906020","phase":"PHASE2","title":"A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2016-12-15","conditions":["Parkinson's Disease"],"enrollment":273,"completionDate":"2021-05-27"},{"nctId":"NCT02574286","phase":"PHASE4","title":"Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2016-06-29","conditions":["Gaucher Disease"],"enrollment":21,"completionDate":"2020-11-30"},{"nctId":"NCT04268030","phase":"","title":"High Order Spectral Analysis of Local Field Potential Data on a Subgroup of Parkinson's Disease Patients Who Are Carriers of Mutations in the Glucocerebrosidase (GBA) Gene Undergoing DBS Electrode Placement","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2020-02-11","conditions":["Parkinson Disease"],"enrollment":9,"completionDate":"2020-08-30"},{"nctId":"NCT00430625","phase":"PHASE3","title":"A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2007-02-15","conditions":["Gaucher Disease, Type 1"],"enrollment":25,"completionDate":"2009-04-01"},{"nctId":"NCT01614574","phase":"PHASE3","title":"Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2012-03-02","conditions":["Gaucher Disease"],"enrollment":6,"completionDate":"2013-05-25"},{"nctId":"NCT00391625","phase":"PHASE1,PHASE2","title":"Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)","status":"COMPLETED","sponsor":"Shire","startDate":"2004-09-13","conditions":["Gaucher Disease"],"enrollment":10,"completionDate":"2008-01-31"},{"nctId":"NCT01842841","phase":"PHASE3","title":"Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2013-03-13","conditions":["Gaucher Disease"],"enrollment":5,"completionDate":"2014-10-08"},{"nctId":"NCT01685216","phase":"PHASE1,PHASE2","title":"Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2012-09-14","conditions":["Gaucher Disease, Type 3"],"enrollment":7,"completionDate":"2015-03-15"},{"nctId":"NCT00635427","phase":"PHASE3","title":"An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2008-03-13","conditions":["Gaucher Disease, Type 1"],"enrollment":95,"completionDate":"2012-12-28"},{"nctId":"NCT00478647","phase":"PHASE2,PHASE3","title":"Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase","status":"COMPLETED","sponsor":"Shire","startDate":"2007-07-25","conditions":["Gaucher Disease"],"enrollment":40,"completionDate":"2009-06-26"},{"nctId":"NCT00553631","phase":"PHASE3","title":"Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2008-01-29","conditions":["Gaucher Disease, Type 1"],"enrollment":34,"completionDate":"2009-05-05"},{"nctId":"NCT00954460","phase":"","title":"Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease","status":"APPROVED_FOR_MARKETING","sponsor":"Shire","startDate":"","conditions":["Gaucher Disease, Type 1"],"enrollment":0,"completionDate":""},{"nctId":"NCT04787887","phase":"PHASE1","title":"A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers","status":"COMPLETED","sponsor":"ISU Abxis Co., Ltd.","startDate":"2020-01-29","conditions":["Gaucher Disease"],"enrollment":42,"completionDate":"2020-10-26"},{"nctId":"NCT03702361","phase":"PHASE4","title":"Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2018-09-04","conditions":["Primary Disease"],"enrollment":15,"completionDate":"2021-03-18"},{"nctId":"NCT03811496","phase":"","title":"Biomarker Analysis for GBA Associated Parkinson's Disease","status":"UNKNOWN","sponsor":"Lysosomal and Rare Disorders Research and Treatment Center, Inc.","startDate":"2018-02-01","conditions":["Parkinson Disease","Gaucher Disease"],"enrollment":100,"completionDate":"2020-07"},{"nctId":"NCT01132690","phase":"PHASE4","title":"A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":["Gaucher Disease"],"enrollment":11,"completionDate":"2012-07"},{"nctId":"NCT00705939","phase":"PHASE3","title":"Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":["Gaucher Disease"],"enrollment":45,"completionDate":"2013-08"},{"nctId":"NCT00712348","phase":"PHASE3","title":"Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12","conditions":["Gaucher Disease"],"enrollment":31,"completionDate":"2013-05"},{"nctId":"NCT00376168","phase":"PHASE3","title":"A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-08","conditions":["Gaucher Disease"],"enrollment":32,"completionDate":"2009-10"},{"nctId":"NCT00962260","phase":"","title":"Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":["Gaucher Disease"],"enrollment":0,"completionDate":""},{"nctId":"NCT01411228","phase":"PHASE3","title":"A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09","conditions":["Gaucher Disease"],"enrollment":15,"completionDate":"2014-08"},{"nctId":"NCT02528617","phase":"PHASE4","title":"The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2015-07","conditions":["Gaucher Disease Type 1","Gaucher Disease Type 3"],"enrollment":0,"completionDate":"2017-10"},{"nctId":"NCT02770625","phase":"PHASE3","title":"Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"ISU Abxis Co., Ltd.","startDate":"2011-09","conditions":["Gaucher Disease, Type 1"],"enrollment":8,"completionDate":"2014-08"},{"nctId":"NCT00244582","phase":"","title":"Convection-Enhanced Delivery of Glucocerebrosidase to Treat Type 2 Gaucher Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2005-10-22","conditions":["Type 2 Gaucher Disease"],"enrollment":1,"completionDate":"2006-11-03"},{"nctId":"NCT00001289","phase":"","title":"Effects of Enzyme Replacement in Gaucher's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1991-09-23","conditions":["Gaucher's Disease"],"enrollment":70,"completionDate":"2008-03-03"},{"nctId":"NCT00891202","phase":"PHASE3","title":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2009-11","conditions":["Gaucher Disease, Type 1"],"enrollment":40,"completionDate":"2016-01"},{"nctId":"NCT00358150","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-06","conditions":["Gaucher Disease, Type 1","Cerebroside Lipidosis Syndrome","Glucocerebrosidase Deficiency Disease","Glucosylceramide Beta-Glucosidase Deficiency Disease","Gaucher Disease, Non-Neuronopathic Form"],"enrollment":26,"completionDate":"2015-12"},{"nctId":"NCT01074944","phase":"PHASE3","title":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2010-06","conditions":["Gaucher Disease"],"enrollment":170,"completionDate":"2015-10"},{"nctId":"NCT00943111","phase":"PHASE3","title":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2009-09","conditions":["Gaucher Disease, Type 1"],"enrollment":160,"completionDate":"2015-06"},{"nctId":"NCT01344096","phase":"","title":"Thrombocytopathy in Gaucher Disease Patients","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2010-10","conditions":["Gaucher Disease","Thrombocytopathy"],"enrollment":70,"completionDate":"2018-11"},{"nctId":"NCT02107846","phase":"PHASE2","title":"An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112","status":"COMPLETED","sponsor":"Protalix","startDate":"2014-04","conditions":["Gaucher Disease"],"enrollment":10,"completionDate":"2015-12"},{"nctId":"NCT00001416","phase":"PHASE2","title":"Bone Response to Enzyme Replacement in Gaucher's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1993-12","conditions":["Gaucher's Disease"],"enrollment":100,"completionDate":"2000-11"},{"nctId":"NCT01161914","phase":"PHASE3","title":"The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease","status":"WITHDRAWN","sponsor":"ISU Abxis Co., Ltd.","startDate":"2011-01","conditions":["Gaucher Disease"],"enrollment":0,"completionDate":""},{"nctId":"NCT01136304","phase":"","title":"Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)","status":"COMPLETED","sponsor":"University Research Foundation for Lysosomal Storage Diseases, Inc.","startDate":"2010-04","conditions":["Gaucher Disease"],"enrollment":173,"completionDate":"2013-12"},{"nctId":"NCT00364858","phase":"PHASE4","title":"Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2001-12","conditions":["Gaucher Disease, Type 1","Cerebroside Lipidosis Syndrome","Glucocerebrosidase Deficiency Disease","Glucosylceramide Beta-Glucosidase Deficiency Disease","Gaucher Disease, Non-Neuronopathic Form"],"enrollment":95,"completionDate":"2007-02"},{"nctId":"NCT00365131","phase":"PHASE4","title":"A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"1997-12","conditions":["Gaucher Disease Type I","Cerebroside Lipidosis Syndrome","Clucocerebrosidase Deficiency Disease","Glucosylceramide Beta-Glucosidase Deficiency Disease","Gaucher Disease, Non-Neuronopathic Form"],"enrollment":40,"completionDate":"2004-07"},{"nctId":"NCT01747980","phase":"PHASE1","title":"Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients","status":"COMPLETED","sponsor":"Protalix","startDate":"2013-03","conditions":["Gaucher Disease"],"enrollment":16,"completionDate":"2014-03"},{"nctId":"NCT02053896","phase":"","title":"A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease","status":"COMPLETED","sponsor":"ISU Abxis Co., Ltd.","startDate":"2011-05","conditions":["Gaucher Disease"],"enrollment":5,"completionDate":"2012-02"},{"nctId":"NCT01951989","phase":"PHASE2","title":"Intra-monocyte Imiglucerase Kinetics in Gaucher Disease","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2012-11","conditions":["Gaucher Disease"],"enrollment":60,"completionDate":"2016-06"},{"nctId":"NCT01881633","phase":"PHASE1","title":"A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers","status":"COMPLETED","sponsor":"ISU Abxis Co., Ltd.","startDate":"2010-10","conditions":["Gaucher Disease"],"enrollment":24,"completionDate":"2010-11"},{"nctId":"NCT01716741","phase":"NA","title":"Identification of Undiagnosed Gaucher Disease","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2012-08","conditions":["Gaucher Disease"],"enrollment":100,"completionDate":""},{"nctId":"NCT00001410","phase":"PHASE1","title":"PEG-Glucocerebrosidase for the Treatment of Gaucher Disease","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1993-10","conditions":["Gaucher's Disease"],"enrollment":18,"completionDate":"2001-12"},{"nctId":"NCT00001234","phase":"PHASE1","title":"Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1988-01","conditions":["Gaucher's Disease"],"enrollment":120,"completionDate":"2002-04"},{"nctId":"NCT00258778","phase":"PHASE1","title":"Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)","status":"COMPLETED","sponsor":"Protalix","startDate":"2005-11","conditions":["Gaucher Disease"],"enrollment":6,"completionDate":"2006-01"},{"nctId":"NCT00004293","phase":"PHASE2","title":"Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease","status":"UNKNOWN","sponsor":"National Center for Research Resources (NCRR)","startDate":"1999-11","conditions":["Gaucher's Disease"],"enrollment":24,"completionDate":""},{"nctId":"NCT00004294","phase":"PHASE1","title":"Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1999-11","conditions":["Gaucher's Disease"],"enrollment":15,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"121","NDDF":"003586","UNII":"27T56C7KK0","VANDF":"4019586","INN_ID":"6866","RXNORM":"46049","UMLSCUI":"C0102139","chemblId":"CHEMBL1201633","ChEMBL_ID":"CHEMBL1201633","KEGG_DRUG":"D02810","DRUGBANK_ID":"DB00088","SNOMEDCT_US":"109088000","MESH_SUPPLEMENTAL_RECORD_UI":"C070292"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1991-","companyName":"Genzyme","relationship":"Original Developer"}],"publicationCount":97,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"A16AB01","allCodes":["A16AB01"]},"biosimilarFilings":[],"originalDeveloper":"Genzyme","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Sanofi","companyId":"sanofi","modality":"Enzyme","firstApprovalDate":"1991","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:41:09.563608+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}